Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
reverse merger
Biotech
Scancell bids for Nasdaq-listed Neuphoria to raise US profile
As Neuphoria continues to navigate the fallout of its failed social anxiety program, the biotech is mulling an offer from another potential buyer.
James Waldron
Jun 29, 2026 7:55am
Spurned by FDA, Passage Bio finds exit through Remix
Jun 24, 2026 5:20pm
Serapha takes flight with $230M, gene-editing prospect from China
Jun 23, 2026 1:55pm
Treeline sees path to public markets via reverse merger
Jun 8, 2026 10:37am
Rallybio swerves past Candid pothole to land deal with Avenzo
Jun 1, 2026 9:09am
Cash-strapped Quince finds salvation in reverse merger
May 18, 2026 10:32am
